CIK 0001711933
AKYA Akoya Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Jul 10, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Akoya Biosciences, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 82 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2025 | Goldman Myla Lai director | JOther Common Stock | -20,000 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Matthew Winkler director | JOther Common Stock | -984,513 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Robert G Shepler director | JOther Stock Option (Right to Buy)derivative | -16,860 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Common Stock | -9,488 | - | - | 196,250 | Jul 10, 2025 |
| Jul 8, 2025 | John Frederick Ek CFO | JOther Common Stock | -54,452 | - | - | 193,750 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas P Schnettler director | JOther Stock Option (Right to Buy)derivative | -16,860 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Jennifer Kamocsay Chief Legal Officer | JOther Common Stock | -16,772 | - | - | 162,500 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Common Stock | +393,338 | - | - | 813,464 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Common Stock | +62,566 | - | - | 324,703 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Common Stockindirect: Thomas A. Raffin Living Trust dated March 29, 2017 | -234,592 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Common Stock | -28,500 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Common Stock | +331,090 | - | - | 1,144,554 | Jul 10, 2025 |
| Jul 8, 2025 | Jennifer Kamocsay Chief Legal Officer | JOther Common Stock | -162,500 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | John Frederick Ek CFO | JOther Common Stock | -193,750 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | FTax withholding Common Stock | -42,148 | - | - | 282,555 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Common Stock | -196,250 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Stock Option (right to buy)derivative | -35,562 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Matthew Winkler director | JOther Stock Option (Right to Buy)derivative | -16,860 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Goldman Myla Lai director | JOther Stock Option (Right to Buy)derivative | -38,993 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Robert G Shepler director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Common Stockindirect: See footnote 3 | -1,737,712 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas P Schnettler director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Robert G Shepler director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Goldman Myla Lai director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Common Stock | -151,930 | - | - | 130,625 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | FTax withholding Common Stock | -196,866 | - | - | 947,688 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Common Stockindirect: See footnote 4 | -15,937,535 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Jennifer Kamocsay Chief Legal Officer | JOther Employee Stock Option (Right to Buy)derivative | -75,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | John Frederick Ek CFO | JOther Common Stockindirect: Ek Trust Dated November 20, 2020 | -20,000 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Matthew Winkler director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas P Schnettler director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Employee Stock Option (Right to Buy)derivative | -150,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Jennifer Kamocsay Chief Legal Officer | JOther Employee Stock Option (Right to Buy)derivative | -70,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Robert G Shepler director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Common Stock | -947,688 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas P Schnettler director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Stock Option (Right to Buy)derivative | -16,860 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Matthew Winkler director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Common Stock | -130,625 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | John Frederick Ek CFO | JOther Employee Stock Option (Right to Buy)derivative | -160,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Employee Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Goldman Myla Lai director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -393,338 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Goldman Myla Lai director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Matthew Winkler director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Employee Stock Option (Right to Buy)derivative | -62,566 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Stock Option (right to buy)derivative | -44,959 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | John Frederick Ek CFO | JOther Employee Stock Option (Right to Buy)derivative | -70,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Employee Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -331,090 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Scott Mendel director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Employee Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Pascal Bamford Chief Clinical Officer | JOther Employee Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Employee Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -241,592 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Thomas A. Raffin director | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -160,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Niro Ph.D Ramachandran Chief Business Officer | JOther Employee Stock Option (Right tderivative | -70,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -160,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | Brian McKelligon President and CEO | JOther Employee Stock Option (Right to Buy)derivative | -175,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jun 1, 2025 | Pascal Bamford Chief Clinical Officer | FTax withholding Common Stock | -670 | $1.25 | $838 | 205,738 | Jun 2, 2025 |
| Apr 1, 2025 | John Frederick Ek CFO | FTax withholding Common Stock | -16,432 | $1.35 | $22k | 248,202 | Apr 3, 2025 |
| Mar 23, 2025 | Niro Ph.D Ramachandran Chief Business Officer | FTax withholding Common Stock | -2,310 | $1.70 | $3,927 | 287,210 | Mar 25, 2025 |
| Mar 23, 2025 | Brian McKelligon President and CEO | FTax withholding Common Stock | -7,550 | $1.70 | $13k | 420,126 | Mar 25, 2025 |
| Mar 1, 2025 | Niro Ph.D Ramachandran Chief Business Officer | FTax withholding Common Stock | -2,310 | $1.63 | $3,765 | 293,114 | Mar 4, 2025 |
| Mar 1, 2025 | Jennifer Kamocsay Chief Legal Officer | FTax withholding Common Stock | -3,851 | $1.63 | $6,277 | 182,866 | Mar 4, 2025 |
| Mar 1, 2025 | John Frederick Ek CFO | FTax withholding Common Stock | -3,594 | $1.63 | $5,858 | 264,634 | Mar 4, 2025 |
| Mar 1, 2025 | Pascal Bamford Chief Clinical Officer | FTax withholding Common Stock | -1,283 | $1.63 | $2,091 | 208,975 | Mar 4, 2025 |
| Mar 1, 2025 | Brian McKelligon President and CEO | FTax withholding Common Stock | -7,550 | $1.63 | $12k | 435,933 | Mar 4, 2025 |
| Mar 1, 2025 | Niro Ph.D Ramachandran Chief Business Officer | FTax withholding Common Stock | -3,594 | $1.63 | $5,858 | 289,520 | Mar 4, 2025 |
| Mar 1, 2025 | Pascal Bamford Chief Clinical Officer | FTax withholding Common Stock | -2,567 | $1.63 | $4,184 | 206,408 | Mar 4, 2025 |
| Mar 1, 2025 | Brian McKelligon President and CEO | FTax withholding Common Stock | -8,257 | $1.63 | $13k | 427,676 | Mar 4, 2025 |
| Mar 1, 2025 | Jennifer Kamocsay Chief Legal Officer | FTax withholding Common Stock | -3,594 | $1.63 | $5,858 | 179,272 | Mar 4, 2025 |
| Nov 19, 2024 | Brian McKelligon President and CEO | AGrant or award Common Stock | +218,750 | $0.00 | $0 | 443,483 | Nov 21, 2024 |
| Nov 19, 2024 | Niro Ph.D Ramachandran Chief Business Officer | AGrant or award Common Stock | +87,500 | $0.00 | $0 | 295,424 | Nov 21, 2024 |
| Nov 19, 2024 | Pascal Bamford Chief Clinical Officer | AGrant or award Common Stock | +87,500 | $0.00 | $0 | 210,258 | Nov 21, 2024 |
| Nov 19, 2024 | John Frederick Ek CFO | AGrant or award Common Stock | +87,500 | $0.00 | $0 | 268,228 | Nov 21, 2024 |
| Nov 19, 2024 | Jennifer Kamocsay Chief Legal Officer | AGrant or award Common Stock | +87,500 | $0.00 | $0 | 186,717 | Nov 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Pascal BamfordChief Clinical Officer
- John Frederick EkCFO
- Jennifer KamocsayChief Legal Officer
- Goldman Myla Laidirector
- Brian McKelligonPresident and CEO
- Scott Mendeldirector
- Thomas A. Raffindirector
- Niro Ph.D RamachandranChief Business Officer
- Thomas P Schnettlerdirector
- Robert G Sheplerdirector
- Matthew Winklerdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.